Welcome to our dedicated page for Sionna Therapeutics news (Ticker: SION), a resource for investors and traders seeking the latest updates and insights on Sionna Therapeutics stock.
Sionna Therapeutics, Inc. (Nasdaq: SION) is a clinical-stage biopharmaceutical company focused on cystic fibrosis, and its news flow reflects ongoing progress in this specialized area of drug development. Company announcements frequently describe advances in its pipeline of small molecule nucleotide binding domain 1 (NBD1) stabilizers and complementary CFTR modulators designed to improve CFTR protein function.
News items for SION often cover key clinical milestones, such as initiation of the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis, and the Phase 1 trial assessing SION-451 in dual combinations with SION-2222 and SION-109 in healthy volunteers. Updates may include information on trial design, target patient populations, measures of CFTR function such as sweat chloride levels, and the rationale for combining NBD1 stabilizers with existing therapies.
Investors and observers can also find press releases on Phase 1 data, including reports that SION-719 and SION-451 were generally well tolerated and exceeded target exposure levels, as well as preclinical findings that NBD1 stabilizers increased the half-life of F508del-CFTR protein to levels seen with wild-type CFTR. Additional news highlights Sionna’s participation in scientific meetings like the North American Cystic Fibrosis Conference and appearances at healthcare and investor conferences.
This SION news page aggregates these disclosures, allowing readers to follow developments in Sionna’s CF-focused programs, track clinical and preclinical data releases, and monitor corporate updates that the company furnishes through press releases and related communications.
Sionna Therapeutics (Nasdaq: SION) initiated the PreciSION CF Phase 2a randomized, double-blind, placebo-controlled crossover trial of SION-719, a first-in-class NBD1 stabilizer, added to Trikafta as standard of care in adults homozygous for F508del with cystic fibrosis. The trial will assess safety, tolerability, PK and change in CFTR function measured by sweat chloride. Topline data are anticipated in mid-2026. Earlier Phase 1 data showed SION-719 was generally well tolerated and exceeded PK targets; a drug-drug interaction study with midazolam supported dosing with Trikafta.
Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), will present data at the 2025 North American Cystic Fibrosis Conference (NACFC) in Seattle from October 22-25, 2025.
The company will showcase two presentations: a workshop discussing safety and pharmacokinetics data from Phase 1 trials of their novel NBD1 stabilizers SION-719 and SION-451, and a poster presentation about small molecule stabilizers' effects on F508del-CFTR. Both presentations will be available on Sionna's website under the Scientific Presentations section.
Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), has appointed Caroline Stark Beer, MBA as Chief Business Officer. Beer brings over 20 years of life science industry experience, most recently serving as CBO at Jnana Therapeutics until its acquisition by Otsuka Pharmaceutical.
Beer's previous experience includes a decade at Alnylam Pharmaceuticals where she served as VP of Business Development, leading significant partnerships including a 5-year collaboration with Regeneron Pharmaceuticals. She holds an MBA from MIT Sloan School of Management and previously worked at Amicus Therapeutics and Bain & Company.
Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, has announced its participation in two major healthcare investor conferences in September 2025.
The company will participate in fireside chats at the Cantor Global Healthcare Conference on September 3rd at 1:35 p.m. ET and the Morgan Stanley Global Healthcare Conference on September 8th at 7:00 a.m. ET. Both events will be held in New York and will be available via webcast on the company's investor relations website.
Sionna Therapeutics (NASDAQ:SION) has initiated dosing in a Phase 1 trial evaluating SION-451, their first-in-class NBD1 stabilizer, in dual combinations with SION-2222 and SION-109 for cystic fibrosis treatment. The randomized, double-blind, placebo-controlled trial in healthy volunteers will assess safety, tolerability, and pharmacokinetics of these combinations.
The study targets cystic fibrosis, a genetic disease affecting over 100,000 people globally. The trial's significance lies in SION-451 being the first NBD1-anchored treatment approach, with topline data expected in mid-2026. Previous Phase 1 trials showed SION-451 was generally well-tolerated and achieved PK concentration targets suggesting potential clinical benefits, including possible wild-type levels of CFTR function.
Sionna Therapeutics (NASDAQ:SION) reported Q2 2025 financial results and provided key updates on its cystic fibrosis (CF) drug development programs. The company announced positive Phase 1 data for its first-in-class NBD1 stabilizers, SION-719 and SION-451, which demonstrated favorable tolerability and exceeded pharmacokinetic targets.
The company plans to initiate a Phase 2a proof-of-concept trial for SION-719 as an add-on therapy in H2 2025, with topline data expected mid-2026. Additionally, SION-451 will advance to Phase 1 trials in dual combinations. Financially, Sionna reported a net loss of $18.1 million and maintains a strong cash position of $337.3 million, expected to fund operations into 2028.